As filed with the Securities and Exchange Commission on March 16, 2022

Registration No. 333-                

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

Satsuma Pharmaceuticals, Inc.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   2834   81-3039831

(State or other jurisdiction of

incorporation or organization)

  

(Primary Standard Industrial

Classification Code Number)

  

(I.R.S. Employer

Identification Number)

400 Oyster Point Boulevard, Suite 221

South San Francisco, CA 94080

(650) 410-3200

(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

2019 Incentive Award Plan,

2019 Employee Stock Purchase Plan

(Full Title of the Plan)

John Kollins

President and Chief Executive Officer

Satsuma Pharmaceuticals, Inc.

400 Oyster Point Boulevard, Suite 221

South San Francisco, CA 94080

(650) 410-3200

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

 

Copies to:

Brian J. Cuneo

Latham & Watkins LLP

140 Scott Drive

Menlo Park, California 94025

Telephone: (650) 328-4600

  

Tom O’Neil

Chief Financial Officer

Satsuma Pharmaceuticals, Inc.

400 Oyster Point Boulevard, Suite 221

South San Francisco, CA 94080

Telephone: (650) 410-3200

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   ☐    Accelerated filer   ☐
Non-accelerated filer   ☒    Smaller reporting company   ☒
     Emerging growth company   ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

 

EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 1,577,277 shares of the Registrant’s common stock issuable under the following employee benefit plans for which Registration Statements of the Registrant on Form S-8 (File No. 333-233808, 333-237058 and 333-254737) is effective: (i) the 2019 Incentive Award Plan, as a result of the operation of an automatic annual increase provision therein, which added 1,261,822 shares of common stock, and (ii) the 2019 Employee Stock Purchase Plan, as a result of the operation of an automatic annual increase provision therein, which added 315,455 shares of common stock.

INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON

FORM S-8

Pursuant to Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Securities and Exchange Commission on September 17, 2019 (File No. 333-233808), March 10, 2020 (File No.  333-237058) and March 26, 2021 (File No. 333-254737) is incorporated by reference herein.

Exhibit Index

 

         Incorporated by Reference     

Exhibit
Number

  

Exhibit Description

    Form    Date    Number    Filed
Herewith
4.1   Amended and Restated Certificate of Incorporation.    8-K    9-17-19    3.1   
4.2   Amended and Restated Bylaws.    8-K    9-17-19    3.2   
4.3   Form of Common Stock Certificate.    S-1/A    9-3-19    4.2   
5.1   Opinion of Latham & Watkins LLP.             X
23.1   Consent of independent registered public accounting firm.             X
23.2   Consent of Latham & Watkins LLP (included in Exhibit 5.1).             X
24.1   Power of Attorney. Reference is made to the signature page to the Registration Statement.             X
99.1(a)#   2019 Incentive Award Plan.    S-1/A    9-3-19    10.4(a)   
99.1(b)#   Form of Stock Option Grant Notice and Stock Option Agreement under the 2019 Incentive Award Plan.    S-1    8-16-19    10.5(b)   
99.1(c)#   Form of Restricted Stock Award Grant Notice under the 2019 Incentive Award Plan.    S-1    8-16-19    10.5(c)   
99.1(d)#   Form of Restricted Stock Unit Award Grant Notice under the 2019 Incentive Award Plan.    S-1    8-16-19    10.5(d)   
99.2#   2019 Employee Stock Purchase Plan.    S-1/A    9-3-19    10.6   
107.1   Fee Filing Table             X

 

#

Indicates management contract or compensatory plan.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in South San Francisco, California.

 

    Satsuma Pharmaceuticals, Inc.
Date: March 15, 2022     By:   /s/ John Kollins
      John Kollins
      Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each John Kollins and Tom O’Neil his or her true and lawful attorneys-in-fact and agents, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons on behalf of the Registrant, in the capacities and on the dates indicated.

 

Signature

   

Title

  

Date

/s/ John Kollins

John Kollins

   

President and Chief Executive Officer

and Director

(Principal Executive Officer)

   March 15, 2022

/s/ Tom O’Neil

Tom O’Neil

   

Chief Financial Officer

(Principal Financial and Accounting Officer)

   March 15, 2022

/s/ Mutya Harsch

Mutya Harsch

    Director   March 15, 2022

/s/ Heath Lukatch

Heath Lukatch

    Director   March 15, 2022

/s/ Thomas B. King

Thomas B. King

    Director   March 15, 2022

/s/ Michael Riebe

Michael Riebe

    Director   March 15, 2022

/s/ Elisabeth Sandoval

Elisabeth Sandoval

    Director   March 15, 2022

/s/ Rajeev Shah

    Director   March 15, 2022
Rajeev Shah     

/s/ Thomas Soloway

    Director   March 15, 2022
Thomas Soloway     

/s/ Ken Takanashi

    Director   March 15, 2022
Ken Takanashi     

 

Satsuma Pharmaceuticals (NASDAQ:STSA)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Satsuma Pharmaceuticals Charts.
Satsuma Pharmaceuticals (NASDAQ:STSA)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Satsuma Pharmaceuticals Charts.